Trial Profile
Randomized Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Patients With Advanced Non-small Cell Lung Cancer: Dual-agent Molecular Targeting of EGFR (DATE)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Gefitinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms DATE
- 29 Dec 2011 New trial record